![]() |
|
|
Chemistry Section, Laboratory of Comparative Carcinogenesis
(R.W.N., K.H.D., R.A.L.) and
Biological Carcinogenesis and Development
Program, The ability of the benzodiazepines, as a chemical class, to cause
the induction and/or inhibition of cytochromes P450 has not been well
characterized. In the present study, the induction of the cytochrome
P450 2B subfamily (CYP2B) in vivo and the inhibition of
CYP2B activity in vitro by selected benzodiazepines was
examined in hepatic tissues derived from male F344/NCr rats. Initial
studies of the in vivo induction or in vitro
inhibition of benzyloxyresorufin O-dealkylation activity revealed that
both clonazepam and diazepam were relatively effective in
vivo inducers of CYP2B when administered in the diet at 500 ppm
for 5 days and also were fairly potent inhibitors of the activity of
these hemoproteins in vitro. Oxazepam, in contrast, was
ineffective as an inducer or an inhibitor of this activity. Further
studies were performed to characterize the subfamily selectivity of the
P450 induction and inhibition displayed by clonazepam. Specifically,
microsomes from rats treated with clonazepam (1000 or 1800 ppm in the
diet for 5 days) were found to be highly induced with respect to
catalytic activities mediated by CYP2B, including benzyloxyresorufin
and pentoxyresorufin O-dealkylation or testosterone
16
-hydroxylation, but other CYP proteins were minimally induced. In
addition to inducing the CYP2B subfamily, clonazepam also induced the
RNA encoding other drug metabolizing enzymes (e.g., epoxide
hydrolase and the glutathione S-transferase
-subfamily) that are
typically induced by phenobarbital-type inducers. Finally, clonazepam
proved to be a potent noncompetitive or "mixed-type" competitive
inhibitor of catalytic activities mediated by CYP2B, but not by other
CYP proteins (e.g. CYP2A, CYP3A) in microsomes derived from
phenobarbital-pretreated rats.
Copyright © 1997 by The American Society for Pharmacology and Experimental Therapeutics
This article has been cited by other articles:
![]() |
T. Kakkar, Y. Pak, and M. Mayersohn Evaluation of a Minimal Experimental Design for Determination of Enzyme Kinetic Parameters and Inhibition Mechanism J. Pharmacol. Exp. Ther., June 1, 2000; 293(3): 861 - 869. [Abstract] [Full Text] |
||||